Literature DB >> 33633413

The Long-Term Efficacy of Radiofrequency Ablation With and Without Steroid Injection.

Alaa Abd-Elsayed1, Michael Loebertman1, Peter Huynh1, Ivan Urits1, Omar Viswanath1, Nalini Sehgal1.   

Abstract

Background: Radiofrequency ablation (RFA) has been proven to be an effective option for treating chronic low back pain. In addition to RFA as a treatment modality, the administration of concomitantly to minimize the effect of hyperalgesia is common practice. However, there is insufficient evidence about the long-term outcomes of their use.
Methods: This was a retrospective study that examined 239 patients who received spine, knee joint, and sacroiliac joint RFA between June 2014 and June 2018. Pre- and post-procedure pain scores, percent improvements, and duration of relief were included in our review. Subjects: This study included 239 patients of which 191 patients received steroids with their RFA.
Results: These 191 patients experienced an average improvement of 48.48% relief for an average of 137.52 days. Forty-eight patients did not receive steroids with RFA and had an average improvement of 46.36% for an average of 126.10 days. The statistical analysis revealed there was no significant difference between the two groups for percent improvement (p = 0.71) and duration of relief (p = 0.67). Conclusions: Patients who received steroids with RFA compared to RFA alone did not differ significantly in percent improvement in pain and duration of relief.
Copyright © 1964–2019 by MedWorks Media Inc, Los Angeles, CA All rights reserved. Printed in the United States.

Entities:  

Keywords:  knee pain; lumbar back pain; radiofrequency ablation; steroid injection

Mesh:

Year:  2020        PMID: 33633413      PMCID: PMC7901125     

Source DB:  PubMed          Journal:  Psychopharmacol Bull        ISSN: 0048-5764


  8 in total

1.  Efficacy and validity of radiofrequency neurotomy for chronic lumbar zygapophysial joint pain.

Authors:  P Dreyfuss; B Halbrook; K Pauza; A Joshi; J McLarty; N Bogduk
Journal:  Spine (Phila Pa 1976)       Date:  2000-05-15       Impact factor: 3.468

2.  The effect of pentoxifiline on post-injury hyperalgesia in rats and postoperative pain in patients.

Authors:  J Wordliczek; A M Szczepanik; M Banach; J Turchan; M Zembala; M Siedlar; R Przewlocki; W Serednicki; B Przewlocka
Journal:  Life Sci       Date:  2000-02-11       Impact factor: 5.037

3.  Pentoxifylline attenuates the development of hyperalgesia in a rat model of neuropathic pain.

Authors:  Jian Liu; Xiaomei Feng; Min Yu; Weiying Xie; Xin Zhao; Weiyan Li; Ren Guan; Jianguo Xu
Journal:  Neurosci Lett       Date:  2006-11-30       Impact factor: 3.046

4.  Radiofrequency denervation with or without addition of pentoxifylline or methylprednisolone for chronic lumbar zygapophysial joint pain.

Authors:  Jan Dobrogowski; Anna Wrzosek; Jerzy Wordliczek
Journal:  Pharmacol Rep       Date:  2005 Jul-Aug       Impact factor: 3.024

5.  The Impact of Local Steroid Administration on the Incidence of Neuritis following Lumbar Facet Radiofrequency Neurotomy.

Authors:  Jaspal R Singh; Vincent F Miccio; Devas J Modi; Michael T Sein
Journal:  Pain Physician       Date:  2019-01       Impact factor: 4.965

6.  Comparison of Efficacy of Lateral Branch Pulsed Radiofrequency Denervation and Intraarticular Depot Methylprednisolone Injection for Sacroiliac Joint Pain.

Authors:  Kaustuv Dutta; Samarjit Dey; Prithwis Bhattacharyya; Sharat Agarwal; Priyanka Dev
Journal:  Pain Physician       Date:  2018-09       Impact factor: 4.965

7.  Efficacy of combined treatment with medial branch radiofrequency neurotomy and steroid block in lumbar facet joint arthropathy.

Authors:  Chinmoy Roy; Nilay Chatterjee; Sudeshna Ganguly; Robin Sengupta
Journal:  J Vasc Interv Radiol       Date:  2012-12       Impact factor: 3.464

8.  Radiofrequency lumbar facet denervation: analysis of prognostic factors.

Authors:  Richard B North; Misop Han; Marianna Zahurak; David H Kidd
Journal:  Pain       Date:  1994-04       Impact factor: 6.961

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.